Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo

Cancer Research

Volumn 61, Issue 7, 2001, Pages 2983-2995

  Jacobs, Andreas ^a,b,c   Tjuvajev, Juri G ^a   Dubrovin, Michael ^a   Akhurst, Timothy ^a   Balatoni, Julius ^a   Beattie, Bradley ^a   Joshi, Revathi ^a   Finn, Ronald ^a   Larson, Steven M ^a   Herrlinger, Ulrich ^b   Pechan, Peter A ^b   Chiocca, E Antonio ^b   Breakefield, Xandra O ^b   Blasberg, Ronald G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; ONCOLYTIC VIRUS; THYMIDINE KINASE; URACIL DERIVATIVE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME SUBSTRATE; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE EXPRESSION; GLIOSARCOMA; HERPES SIMPLEX VIRUS 1; NONHUMAN; PLAQUE FORMING CELL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TRANSGENE; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; ARABINOFURANOSYLURACIL; AUTORADIOGRAPHY; CERCOPITHECUS AETHIOPS; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; GLIOMA; GLIOSARCOMA; HERPESVIRUS 1, HUMAN; HUMANS; IODINE RADIOISOTOPES; LAC OPERON; MICE; MICE, NUDE; MUTATION; RATS; THYMIDINE KINASE; TOMOGRAPHY, EMISSION-COMPUTED; TRANSGENES; VERO CELLS; VIRUS REPLICATION;

EID: 0035300468     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Human gene marker/therapy clinical protocols
2. The TMC worldwide gene therapy enrollment report, 1996
3. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
4. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
5. A Phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir
6. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/CYP2BI and ganciclovir/HSV-TK gene therapies
7. Gene therapy for tumors of the central nervous system
8. HSV-1 based vectors for gene therapy of neurological diseases and brain tumors. Part II. Vector systems and applications
9. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization
10. In situ use of suicide genes for therapy of brain tumours
11. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors
12. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase
13. Herpes simplex virus vectors for tumor therapy
14. B-myb promoter re-targeting of herpes simplex virus γ34.5-mediated virulence towards tumor and cycling cells
15. Engineering herpes simplex virus vectors for gene transfer to neurons
16. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy
17. Experimental therapy of human glioma by means of a genetically engineered virus mutant
18. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours-evaluation of a potentially effective clinical therapy
19. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
20. Transcriptional targeting of herpes simplex virus for cell-specific replication
21. Herpes virus targeting of glioblastomas
22. Act locally, think globally
23. Toxicity evaluation of replication competent herpes simplex virus (ICP34.5 null mutant 1716) in patients with recurrent malignant glioma
24. HSV-1 based vectors for gene therapy of neurological diseases and brain tumors. Part 1. HSV-1 structure, replication and pathogenesis
25. β-Galactosidase as a marker in the peripheral and neural tissues of the herpes simplex virus-infected mouse
26. Expanded spectrum of viral therapy in the treatment of nervous system tumors
27. Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1
28. Toxicity studies in thymidine kinase-deficient herpes simplex virus therapy for malignant astrocytoma
29. Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats
30. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant
31. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant
32. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene
33. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a SCID mouse model of human malignant glioma
34. Mapping of herpes simplex virus-1 neurovirulence to γ1 (34.5), a gene nonessential for growth in culture
35. Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2
36. Herpes simplex viruses and their replication
37. Deoxythymidine kinase of E. Coli. Kinetics and feedback control
38. Novel (E)-5-(2-iodovinyl)-2′-deoxyuridine derivatives as potential cytostatic agents against herpes simplex virus thymidine kinase gene transfected tumors
39. Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir
40. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography
41. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography
42. Imaging transgene expression with radionuclide technologies
43. Monitoring of herpes simplex virus thymidine kinase enzyme activity using positron emission tomography
44. Imaging the expression of transfected genes in vivo
45. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: A potential method for monitoring clinical gene therapy
46. Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography
47. Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo
48. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis
49. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors
50. Synthesis and quality assurance of radioiodinated 2′-fluoro-2′-deoxy-1-β-D-arabinofuranosyl-5-iodo-uracil
51. Nucleosides, 110. Synthesis and antiherpes virus activity of some 2′-fluoro-2′-deoxyarabinofuranosylpyrimidine nucleosides
52. Low energy cyclotron production and chemical separation of "no carrier added" iodine-124 from a reusable, enriched tellurium-124 oxide/aluminum oxide solid solution target
53. Production and quality assurance of cyclotron produced iodine-124 from enriched tellurium targets
54. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy
55. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins
56. The relative stability of selected herpes simplex virus type 1 mRNAs
57. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors
58. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector
59. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector
60. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses
61. Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS
62. In vivo magnetic resonance imaging of transgene expression
63. The development of in vivo imaging systems to study gene expression
64. In vivo imaging of oligonucleotides with positron emission tomography